Welcome to our dedicated page for Align Technology news (Ticker: ALGN), a resource for investors and traders seeking the latest updates and insights on Align Technology stock.
Align Technology reports developments in digital orthodontics and restorative dentistry through its Invisalign System of clear aligners, iTero intraoral scanners, exocad CAD/CAM software and the Align Digital Platform. Company news commonly covers product and workflow updates for clear-aligner treatment planning, intraoral scanning, 3D visualization and digitally connected dental practices.
Recurring updates also include quarterly and annual operating results, clear-aligner shipment and channel trends, regional demand, foreign-exchange effects, stock repurchase activity, financial-conference participation and governance or shareholder-voting matters. Other announcements describe clinical education, professional collaborations and access-to-care initiatives involving orthodontists, general practitioner dentists and dental research organizations.
Align Technology (ALGN)/b) will present at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026.The presentation is scheduled from 3:10–3:40 p.m. ET in New York, NY, with remarks by John Morici, EVP Global Finance and CFO, and Madelyn Valente, Director, Corporate Communications and Investor Relations. The session will be webcast live via the Investor Relations section of Align’s website, with an archived replay available for about one month.
Align Technology (Nasdaq: ALGN) appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors effective immediately and announced the planned retirement of director Andrea L. Saia effective September 23, 2026. Blackford brings senior leadership experience from iRhythm, Dexcom, NuVasive, and Zimmer Holdings, and currently serves on the board of Alphatec Holdings. He will be included in Align’s slate of director nominees for the 2027 Annual Meeting. In connection with his appointment, the Board size increases to 11 directors and, following Saia’s retirement, will return to 10 members.
Align Technology (Nasdaq: ALGN) announced that the Jinan Intermediate People's Court in China issued a first-instance judgment on August 10, 2026, in favor of Align in its 2025 patent infringement action against Angelalign subsidiaries. The court found Angel's use of its MasterForce and ATreat systems to generate A7 and A7 Speed premolar extraction treatment solutions, and related aligner products, infringes Align’s CN113693748B extraction-gap-closure patent, ordered Angel to stop using the patented technology and cease manufacturing and selling the infringing products in China, and awarded Align RMB 10 million in damages. Angel may appeal to the Supreme People's Court. According to Align, this ruling complements a February 2026 UPC preliminary injunction in Europe and ongoing U.S. ITC proceedings, and underscores its strategy of global IP enforcement alongside extensive worldwide manufacturing and treatment-planning operations.
Align Technology (Nasdaq: ALGN) hosted the 2026 Invisalign Ortho Summit in Las Vegas from July 23–26, bringing together more than 500 orthodontists and practice team members under the theme “Beyond Possible.” The event highlighted how the Align Digital Platform connects Invisalign clear aligners, iTero scanners, and exocad software to support more predictable, efficient digital orthodontic workflows.
At the Innovation Hub, Align showcased new and enhanced solutions, including the Invisalign Specifix Attachment System (limited market release), Invisalign integrated buttons, an updated Invisalign Palatal Expander System with integrated hooks, a custom clear-aligner trimline option, and upgrades to Invisalign Outcome Simulator Pro and ClinCheck 3D Tissue Animation. Orthodontist-led sessions focused on complex cases, digital workflow optimization, and practice growth strategies. A clinical study from the University of Insubria was highlighted, reporting that the Invisalign Palatal Expander System effectively widened the upper jaw with controlled, predictable results comparable to a traditional metal Hyrax expander.
Align Technology (Nasdaq: ALGN) announced governance and capital allocation initiatives following discussions with Elliott Investment Management. The company will add three new independent directors, targeting candidates with healthcare, medical device, technology, global operations and high-growth scaling experience to support its next phase of growth.
Align has also begun a comprehensive strategic and operating model review, supported by a global consulting firm, focused on commercial execution, organizational effectiveness, resource optimization and scalability, which Align expects to support sustainable revenue growth and margin expansion. In addition, Align increased its 2026 share repurchase commitment and now plans to buy back $400 million to $500 million of common stock in 2026, which the Board and management state reflects their confidence in Align’s long-term value.
Align Technology (Nasdaq: ALGN) reported Q2'26 revenues of $1.06 billion, up 4.3% year-over-year and 1.5% sequentially, driven by Clear Aligner revenues of $870.9 million (+8.2% YoY) and record shipments of 691.8 thousand cases (+7.4% YoY). Imaging Systems and CAD/CAM Services revenues were $185.3 million, down 10.8% year-over-year amid softer capital equipment demand and a shift to lower-priced scanners and flexible models.
GAAP gross margin was 71.7% and operating margin 14.6%, while non-GAAP gross and operating margins were 72.3% and 22.9%, both up year-over-year. GAAP diluted EPS was $1.51 and non-GAAP EPS $2.64, with foreign exchange reducing EPS by $0.23 year-over-year. Cash and equivalents reached $1.10 billion and the company repurchased about 0.4 million shares for $67 million. Align recorded an estimated $37.5 million UK VAT-related liability and guided Q3'26 revenues to $1.00–$1.02 billion, sequentially lower, while reaffirming 2026 revenue growth of 3–4%.
Align Technology (Nasdaq: ALGN) announced multiple new features across its integrated Align™ Digital Platform to enhance Invisalign® treatment planning, diagnostics, and patient engagement. Updates span Align™ Oral Health Suite, Invisalign® Outcome Simulator Pro, ClinCheck® 3D Tissue Animation, iTero™ Design Suite, and Invisalign Smile Architect™.
Align Oral Health Suite now integrates AI-powered Align™ X-ray Insights and a gumline visualization tool to help doctors explain interproximal cavities and potential gum recession. Invisalign Outcome Simulator Pro adds Arch control and an Occlusogram for in‑face, interactive treatment simulations. A new ClinCheck 3D Tissue Animation feature lets doctors simulate facial soft tissue changes by the end of Invisalign treatment, supporting aesthetic-focused planning.
Workflow enhancements include AI-powered crown & bridge and splint design in iTero Design Suite, plus new preferences templates and Dual Flex Rx options in Invisalign Smile Architect to streamline complex ortho‑restorative cases. Align also highlights recent additions such as the Invisalign Specifix™ Attachment System, digitally integrated buttons, an Invisalign Palatal Expander System with integrated hooks, and a custom trimline option for Invisalign clear aligners.
Align Technology (Nasdaq: ALGN) has been named title sponsor of Operation Smile’s 34th International Student Leadership Conference (ISLC) 2026 in Bangkok, Thailand, from July 17–23, marking its sixth consecutive year in this role.
According to Operation Smile, Align has contributed more than $2 million over six years to student programs and nearly $3.8 million in total to support student and surgical initiatives. ISLC 2026 will host about 280 high school and university participants from 37 countries, including roughly 100 Align Scholar full-scholarship recipients, many with cleft conditions and from low- and middle-income countries.
Align Technology (Nasdaq: ALGN) will report Q2 2026 financial results on Wednesday, July 29, 2026, after market close. Results will be posted at 4:00 p.m. ET on the company’s investor relations website.
A conference call and live audio webcast to discuss results will begin at 4:30 p.m. ET, with an archived webcast available for one month.
Summary not available.